| News
T3 Pharmaceuticals wins W.A. de Vigier Award
28.05.2019
T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer therapy using bacteria.
T3 Pharma (img: Universität Basel, Basile Bornand)
T3 Pharmaceuticals is among the ten winners of this year’s W.A. de Vigier Award. The Basel startup impressed the jury with its targeted cancer therapy. T3 Pharmaceuticals employ living bacteria that have the capacity to specifically find and grow in solid tumors, where the bacteria serve as efficient factories for therapeutically active proteins. The startup was founded in 2015 out of a research project at the Biozentrum of the University of Basel. T3 Pharmaceuticals is a portfolio company of BaseLaunch.
With annual prize money of 500,000 Swiss francs, the W.A. de Vigier promotional award is the oldest and most financially significant award for startups in Switzerland. To mark its 30th anniversary, the W.A. de Vigier Foundation selected twice as many startups to win the award this year. What’s more, 60 startups were able to pitch to the jury rather than the usual 16. This year’s prize money also increased to 750,000 francs overall, with some of the funds being contributed by former award winners.
“I am particularly pleased that former winners contributed to this year’s prize money. I hope that in the future our alumni will increasingly partner up with each other to help established companies remain innovative and pave the way for young startups to enter the market,” said Regula Buob, Managing Director of the W.A. de Vigier Foundation. This is all in the spirit of the founding father Bill de Vigier.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
Healthtech sector growing rapidly in the Basel Area
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
Botnar Research Center advancing research into coronavirus
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
Read More
